Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Abnormal serum phosphate (hypophosphataemia or hyperphosphataemia)

Nephrology · Abnormal laboratory result · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: Among inpatients, moderate hypophosphataemia affects 2 to 3% of patients and severe hypophosphataemia 0.2 to 0.4% (Swiss review, 2019) [1].

Hypophosphataemia (< 0.8 mmol/L)

Fasting sample.

Fasting laboratory tests in the morning

If persistent hypophosphataemia with no obvious cause (TmP/GFR)

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Hyperphosphataemia (> 1.45 mmol/L)

Fasting sample.

Fasting laboratory tests in the morning

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (12)
  1. Bex S, Mollard F, Stirnemann J. Que faire de l'hypophosphatémie ? Rev Med Suisse. 2019;15:1871-5.
  2. Aljuraibah F, Bacchetta J, Brandi ML, et al. An expert perspective on phosphate dysregulation with a focus on chronic hypophosphatemia. J Bone Miner Res. 2022;37(1):12-20.
  3. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1139 (25-OH-vitamine D) et 0983 (parathormone).
  4. National Institute for Health and Care Excellence. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. Clinical guideline CG32, 2006, mise à jour 2017 : recommandation 1.4.6 (encadré 1).
  5. ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit FERINJECT 50 mg Fer/mL (carboxymaltose ferrique), rubriques 4.4 et 4.8, et notice, consulté le 11 octobre 2026.
  6. Agence européenne des médicaments. Viread (ténofovir disoproxil) : résumé des caractéristiques du produit (information produit EPAR), rubrique 4.4, consulté le 11 octobre 2026.
  7. Medicines and Healthcare products Regulatory Agency (Royaume-Uni). Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures. Drug Safety Update, 16 novembre 2020 (note complémentaire de septembre 2026).
  8. US Food and Drug Administration, American Regent. INJECTAFER (ferric carboxymaltose injection), prescribing information, boxed warning « Symptomatic hypophosphatemia » (08/2026), notice DailyMed du 19 août 2026.
  9. Dabir M, Mousavi MK, Mohamadi M, Maleki A. Pseudohyperphosphatemia in multiple myeloma: a systematic review of case reports and case series. J Clin Lab Anal. 2026;40(15):e70281.
  10. Haute Autorité de santé, Centre de référence des maladies rares du métabolisme du calcium et du phosphate. Protocole national de diagnostic et de soins (PNDS) : Hypoparathyroïdie. Mars 2025.
  11. National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. NICE guideline NG203, 25 août 2021 (dernière mise à jour 24 novembre 2021) : recommandations sur le métabolisme osseux.
  12. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.